FDA Reiterates Preference For Overall Survival Data For Lung Cancer Approvals
Executive Summary
FDA’s final guidance on lung cancer trial endpoints says that overall survival is the optimal test of efficacy, but reaffirms that progression-free survival primary endpoint may support approval if the magnitude of effect is “substantial and statistically robust.”